• Provirex

  Participated · Equity · Aug 2026

  Provirex traces its scientific origins to research beginning in 2007 and was founded as a spin-off in 2019 to commercialize the Brec1 recombinase technology that cuts out integrated HIV DNA from infected T-helper cells. Preclinical studies demonstrated efficacy in human cells implanted into mice with favorable immunological and toxicological profiles. The company has built in-house laboratory and production capacity—relocating to a full floor at tecHHub in Altona—and expanded its team to just under 20 employees under CEO Dr. Jan Claas-von Jachmann, who joined in March 2025. Provirex is preparing a first-in-human, ex vivo clinical trial in multiple German university hospitals involving eight patients whose stem cells will be engineered with Brec1 and re-infused following busulfan conditioning. Management plans to conduct production in-house and pursue a longer-term goal of in vivo delivery, targeting a potential large-scale market launch around 2033. Financially, the company has raised seed and follow-on investments from IFB-linked funds, Ascencion, Bioventure and InnoVentureFonds, and reports funding secured through the end of 2027 to advance the clinical program.

• Holy Technologies

  Participated · Equity · Sep 2025

  Founded in 2022, Hamburg-based Holy Technologies is developing an autonomous factory platform for lightweight composite parts, powered by an AI-led robotic fibre-placement process and its proprietary “Holy OS” software layer. The system precisely positions continuous fibres around pins, learning from every build cycle to cut labour, speed production, and enable closed-loop recycling that retains 97–98 % of carbon-fibre integrity. In trials the company delivers 20–30 % weight reductions versus traditional composites and up to 70–80 % versus metals, unlocking performance gains for customers in aerospace, premium automotive, orthopaedics, and energy sectors. Holy has already constructed a fully operational pilot line, secured offtake agreements for thousands of components, and partnered with leading OEMs and Tier-1 suppliers. By automating what is today a largely manual process, the firm aims to return composite manufacturing competitiveness to Europe while advancing true circularity. Future plans include scaling the autonomous factory and expanding production capacity to meet customer demand. The €4.3 million capital raise provides the resources to industrialise the platform and move toward full-scale commercial deployment.

• 3D Spark

  Participated · Seed · May 2025

  3D Spark develops artificial-intelligence software that analyzes and optimizes manufacturing workflows, helping industrial producers cut costs, reduce material usage, and increase overall process transparency. The company’s solution has initially focused on additive manufacturing for the rail sector, but management plans to expand into additional verticals and traditional manufacturing methods. Its technology aims to deliver data-driven recommendations that enable more sustainable production decisions across global supply chains. Earlier this year the startup secured €2 million in seed financing, providing the capital to refine its product and grow its customer base. The newly completed invite-only community round adds a network of seasoned operators and researchers who will contribute deep industry expertise alongside fresh capital. With this support, 3D Spark intends to accelerate international expansion, including a launch in the United States, and to broaden its platform’s applicability beyond additive manufacturing. No revenue or user metrics were disclosed in the article.

• mo:re

  Participated · Seed · Mar 2025

  mo:re provides a laboratory platform that automates the planning, culture, and analysis of complex 3D cell culture models. The platform is designed to deliver verifiable, standardized results without requiring expertise in specific organ systems. Led by CEO Lukas Gaats, the company focuses on complex cell culture workflows and commercialization of its system. mo:re raised €2.3M in Seed funding to accelerate commercialization of its platform. The funding will be used to speed the commercialization of the platform for complex cell culture workflows. The company is based in Hamburg, Germany.

• Flexvelop

  Participated · Equity · Mar 2025

  Flexvelop provides an all-digital financing product called Flexing that blends features of renting, leasing and loans to let SMEs obtain devices immediately without tying up long-term capital. The company processes applications digitally and bears the investment risk while customers can buy or return devices at any time. Offerings cover items from laptops and coffee machines to medical equipment and can scale to large projects of up to 1,000 devices per company. Flexvelop emphasizes speed, cost-efficiency and flexible, customised conditions for business equipment financing. The company has completed a rebrand to signal its transition from an agile startup to an established financing platform and plans to use new funds to build major partnerships and finance larger volumes.

No current team members are available.